StreetAlpha.app
Home › Stocks › TYRA

Tyra Biosciences, Inc. (TYRA)

Healthcare
$19.57
▼ −0.86%
LAST CLOSE · NOV 17

Tyra Biosciences develops oral small molecule drug candidates for cancers and genetically defined conditions, based in Carlsbad, California. It last closed at $19.57 on Nov 17, down 0.86% on the day. The average 12-month price target from 3 analysts is $41.33 (+111.2% from the last close), with a high of $57.00 and a low of $27.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is TYRA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$169.8M
EPS (diluted)
−$2.63
Free cash flow
−$119.8M
Valuation
Market cap
$1.4B
69.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$456.0M
At Sep 30
Shareholder equity
$692.8M
Shares outstanding
69.1M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$26.3M−$26.3MFY2021FY2022: −$55.3M−$55.3MFY2022FY2023: −$69.1M−$69.1MFY2023FY2024: −$86.5M−$86.5MFY2024FY2025: −$119.9M−$119.9MFY2025

From TYRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on TYRA in the past 90 days
Average 12-month target
$41.33
▲ 111.2% upside

Based on 3 analysts who set a price target on TYRA in the past 90 days. The average target is $41.33, with a high of $57.00 and a low of $27.00, compared with the last close of $19.57.

Low $27.00Avg $41.33High $57.00
Blue marker: last close $19.57
Highest target$57.00
Average target$41.33
Lowest target$27.00
Latest rating changes
WedbushMaintained
Nov 11Buy$57
HC Wainwright & Co.Target lowered
Nov 11Buy$29 → $27
OppenheimerReiterated
Sep 22Buy$40
HC Wainwright & Co.Target lowered
Sep 22Buy$30 → $29
HC Wainwright & Co.Target lowered
Sep 10Buy$45 → $30
DateFirmActionRatingPrice target
Nov 11WedbushMaintainedBuy$57
Nov 11HC Wainwright & Co.Target loweredBuy$29 → $27
Sep 22OppenheimerReiteratedBuy$40
Sep 22HC Wainwright & Co.Target loweredBuy$30 → $29
Sep 10HC Wainwright & Co.Target loweredBuy$45 → $30
Loading…

Technical Analysis

TYRA · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 10% below its 50 day average. It is 50% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the Pivot S1 at $19.01, and the nearest resistance the Pivot at $19.90.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 5.9%/day
Key levels
$40.6552 week high+107.7%
$29.30200 day average+49.7%
$25.19100 day average+28.7%
$22.37Swing high (Oct 29)+14.3%
$21.4350 day average+9.5%
$20.8920 day average+6.7%
$20.46Pivot R1+4.5%
$19.90Pivot+1.7%
$19.57Last close
$19.01Pivot S1−2.9%
$18.66Swing low (Sep 9)−4.6%
$14.8452 week low−24.2%
Indicators
RSI (14)40.16Middle of its rangeNeutral
MACD-0.36Below its signal lineBearish
Stochastic14.8Near the bottom of its rangeOversold
ADX (14)10.9No clear trend
Williams %R-91.5Oversold below −80, overbought above −20Oversold
CCI (20)-136.4Oversold below −100, overbought above 100Oversold
Rate of change−8.4%Change over 10 sessionsBearish
ATR (14)$1.15Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TYRA

What happened before

See how TYRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TYRA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TYRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TYRA in the last 90 days.

Loading…

See today’s whale options flow across the market →

TYRA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●80 buying vs 86 selling
  • ▲Held by funds +13.8 pts
  • ▼Funds holding -15
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding155170−8.8%
In funds' top 10770.0%
Held by funds114.3%100.5%+13.8 pts
New / increased22 / 5831 / 73−23.1%
Reduced / sold out51 / 3543 / 26+24.6%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TYRA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TYRA is in one of them and how their past TYRA trades turned out.

TYRA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TYRA in an article yet. Here's the latest on the wider market.

About Tyra Biosciences

Tyra Biosciences is a biotechnology company based in Carlsbad, California. It develops oral medicines for urothelial cancers, which affect the bladder and urinary tract, and for achondroplasia, a bone growth condition in children. Its drug candidates are still in clinical trials and have not been approved for sale. The company designs them with its own in-house platform, aiming to serve patients with these cancers and conditions.

Headquarters
Carlsbad, CA